Therapeutic Interchange for Trelegy
For patients currently on Trelegy (fluticasone furoate/umeclidinium/vilanterol triple therapy), the most appropriate therapeutic interchange is to separate the components into LABA/LAMA dual therapy (such as umeclidinium/vilanterol) plus a separate ICS/LABA combination (such as fluticasone furoate/vilanterol), though this approach uses multiple inhalers rather than single-inhaler triple therapy. 1, 2, 3
Understanding Trelegy Components
Trelegy Ellipta contains three active ingredients delivered in a single inhaler 4, 5:
- Fluticasone furoate (ICS) - 100 mcg
- Umeclidinium bromide (LAMA) - 62.5 mcg
- Vilanterol trifenatate (LABA) - 25 mcg
This combination is FDA-approved for once-daily maintenance treatment of moderate to severe COPD in patients not adequately controlled on ICS/LABA therapy. 2, 3
Direct Therapeutic Alternatives
Option 1: Separate Dual Therapy Inhalers (Preferred for Most Patients)
LABA/LAMA dual therapy should be the primary interchange for patients at low risk of exacerbations, as this approach avoids the increased pneumonia risk associated with ICS while maintaining bronchodilation. 1
- Umeclidinium/vilanterol (Anoro Ellipta) 62.5/25 mcg once daily
- This provides the two bronchodilators from Trelegy without the corticosteroid component 6
- LAMA/LABA combinations demonstrate superior improvements in lung function and lower pneumonia rates compared to ICS/LABA combinations 1
Option 2: ICS/LABA Plus Separate LAMA
For patients requiring continued ICS therapy (those with ≥2 exacerbations per year, blood eosinophils ≥150-200 cells/µL, or asthma-COPD overlap):
- Fluticasone furoate/vilanterol (Breo Ellipta) 100/25 mcg once daily PLUS
- Umeclidinium (Incruse Ellipta) 62.5 mcg once daily 2, 3
- This maintains all three drug classes but requires two separate inhalers 1
Option 3: Alternative Triple Therapy Combinations
If single-inhaler triple therapy is clinically necessary, no exact equivalent exists, but alternative triple combinations include:
- Budesonide/glycopyrrolate/formoterol (Breztri Aerosphere)
- Beclomethasone/glycopyrronium/formoterol (Trimbow)
- These use different specific agents within the same drug classes 7
Clinical Decision Algorithm
Step 1: Assess Exacerbation Risk
Low risk (≤1 moderate exacerbation in past year, no hospitalizations):
- Interchange to LABA/LAMA dual therapy (umeclidinium/vilanterol) 1
- Discontinue ICS component to reduce pneumonia risk 7
High risk (≥2 moderate exacerbations or ≥1 severe exacerbation requiring hospitalization):
- Continue triple therapy with either single-inhaler or multiple-inhaler approach 1
Step 2: Evaluate for Asthma-COPD Overlap
If concomitant asthma features present:
- Maintain ICS component; use ICS/LABA (fluticasone furoate/vilanterol) plus separate LAMA 1
- ICS/LABA combination is preferred over LAMA/LABA in this population 1
If pure COPD without asthma features:
- LAMA/LABA dual therapy is preferred 1
Step 3: Consider Blood Eosinophil Count
Eosinophils ≥150-200 cells/µL:
- Suggests greater ICS responsiveness; maintain triple therapy 1
Eosinophils <150 cells/µL:
- Consider stepping down to LABA/LAMA dual therapy 1
Critical Considerations When Switching
Monitoring After ICS Withdrawal
When stepping down from triple therapy to LABA/LAMA, monitor closely for:
- Worsening health status (CAT score increase) 1
- Decline in lung function (FEV1 decrease) 1
- Increased exacerbation frequency 7
The 2023 Canadian Thoracic Society guideline provides only a weak recommendation to continue triple therapy rather than stepping down in symptomatic patients, reflecting equipoise in the evidence. 1
Pneumonia Risk Considerations
ICS therapy increases pneumonia risk, particularly in severe COPD. 8, 7
- This risk is dose-dependent and increases with disease severity 7
- Regular ICS treatment shows a 4% increased pneumonia risk compared to LABA alone 8
- For patients with recurrent pneumonia, strongly consider removing ICS component 7
Device and Adherence Factors
Single-inhaler triple therapy improves adherence compared to multiple inhalers. 5, 9
- If adherence is a concern, maintaining single-inhaler triple therapy may be preferable to multiple-inhaler regimens 5, 10
- The Ellipta device demonstrates good patient acceptance and proper technique 5
Common Pitfalls to Avoid
Do not use LABA monotherapy - this increases risk of serious asthma-related events in patients with any asthma component. 2, 3
Do not combine with additional LABA-containing products - risk of overdose and cardiovascular effects. 2, 3
Do not abruptly discontinue ICS in patients on chronic therapy - taper slowly to avoid adrenal insufficiency, particularly in those previously on systemic corticosteroids. 2, 3
Avoid beta-blocking agents (including ophthalmic preparations) in all COPD patients as they antagonize bronchodilator effects. 11
Do not use for acute symptom relief - Trelegy and all maintenance therapies are not indicated for acute bronchospasm; patients require separate rescue inhalers. 2, 3